OVIDREL (choriogonadotropin alfa) by Merck & Co. is clinical pharmacology the physicochemical, immunological, and biological activities of recombinant hcg are comparable to those of placental and human pregnancy urine-derived hcg. First approved in 2000.
Drug data last refreshed 28m ago · AI intelligence enriched 2w ago
OVIDREL (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin (hCG) analog administered by subcutaneous injection for ovulation induction in assisted reproductive technology. It mimics the luteinizing hormone (LH) surge to trigger final follicle maturation and oocyte meiosis resumption after FSH-stimulated follicular development. The drug works by binding to LH/hCG receptors on ovarian granulosa and theca cells to induce ovulation.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on retention strategies and lifecycle management.
CLINICAL PHARMACOLOGY The physicochemical, immunological, and biological activities of recombinant hCG are comparable to those of placental and human pregnancy urine-derived hCG. Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of…
Worked on OVIDREL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Gonadotropin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel
A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)
Working on OVIDREL provides exposure to the specialized ART/fertility market segment, requiring deep understanding of patient access, physician relationships, and payer dynamics in reproductive medicine. As the product approaches LOE, career value comes from demonstrating retention skills, lifecycle management expertise, and ability to navigate competitive and regulatory complexity in a niche therapeutic area.